Catalyst Pharmaceutical Partners Inc. announced positive results from a Phase 1a study to evaluate the safety, tolerability and pharmacokinetic profile of CPP-115.
NovaBay Pharmaceuticals Inc. has enrolled the first patients in its Phase 2b clinical study to evaluate its lead compound NVC-422, for treating adenoviral conjunctivitis.
A cancer treatment from Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals Inc. failed to improve overall survival in patients with advanced cases of lung cancer.
Cancer Research UK's Drug Development Office has begun a trial of a drug combination in patients with advanced solid tumors and in patients with non-small cell lung cancer.
Elevation Pharmaceuticals Inc. announced positive results from a Phase 2b study of EP-101 in patients with chronic obstructive pulmonary disease.
Theraclone Sciences Inc. announced positive data from its Phase 1 trial of TCN-032, a broadly protective, fully human monoclonal antibody, for the treatment of influenza A infections.
Ark Therapeutics Group plc has completed the dose ranging Phase 1 section of the academic study of Ark’s VEGF-D adenoviral vector treatment for refractory angina.
Galleon Pharmaceuticals announced that GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase 1 study.
Clinical development is an integral part of launching new drugs to market, and is comprised mainly of conducting clinical trials and submitting the data for approval.
NovaDigm Therapeutics announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.
Otsuka Pharmaceutical Co. Ltd. and H. Lundbeck A/S announced results from a Phase 3 clinical trial evaluating aripiprazole for the treatment of adults with schizophrenia.
Ventrus Biosciences Inc. reported positive results from its Phase 3 clinical trial of diltiazem hydrochloride cream in patients with anal fissures.
Promethera Biosciences has treated its first two patients with its innovative treatment based on allogeneic adult liver stem cell technology, HepaStem.
AesRx LLC has begun a Phase 1/2a clinical trial of Aes-103 in patients with sickle cell disease. This trial is part of an ongoing collaboration with the National Institutes of Health.
TapImmune Inc. has announced that following recent IRB approval a Phase 1 clinical trial on a novel set of HER2/neu Class II antigens will start at Mayo Clinic.
Federal health advisers said that a first-of-a-kind drug from Pfizer appears to be safe and effective for patients with rheumatoid arthritis.
GTx Inc. announced that regulators are allowing it to restart clinical testing of its prostate cancer drug Capesaris. The company said it will start a new mid-stage trial of Capesaris during the third quarter of 2012.
Macrocure has achieved positive results for a Phase 4 trial of its lead product, CureXcell, for the treatment of hard-to-heal ulcers in a community care setting.
Halo Therapeutics LLC announced that the European Commission has granted orphan medicinal product designation to HT-100 for the treatment of Duchenne muscular dystrophy.
A second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor has failed in testing.
Genentech announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy of subcutaneous Actemra to intravenous Actemra.
The world's largest drugmaker, Pfizer, halted a late-stage study of its second-best selling drug, Lyrica, as a possible treatment for a nerve pain in HIV patients.
A Phase 2 study has compared a combination of ficlatuzumab and gefitinib to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer.
Gilead Sciences Inc. announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.